Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
  2. >
  3. Stock
  4. >
  5. CLBT
stocks logo

CLBT

-
Add to WatchlistAdvanced Chart
$
0.000
0.000(0.000%)
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
112.21M
+17.23%
0.107
+6.96%
124.36M
+16.38%
0.127
-9.5%
130.86M
+20%
0.131
+30.91%
Estimates Revision
The market is revising No Change the revenue expectations for Cellebrite DI Ltd. (CLBT) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -23.41%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-23.41%
In Past 3 Month
7 Analyst Rating
up Image0
Wall Street analysts forecast CLBT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLBT is 23.25 USD with a low forecast of 20.00 USD and a high forecast of 25.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
0 Hold
0 Sell
Strong Buy
up Image0
Current: 14.590
sliders
Low
20.00
Averages
23.25
High
25.00
up Image0
Current: 14.590
sliders
Low
20.00
Averages
23.25
High
25.00
JPMorgan
Overweight
downgrade
$22 -> $20
2025-06-23
Reason
JPMorgan
Price Target
$22 -> $20
2025-06-23
downgrade
Overweight
Reason
JPMorgan lowered the firm's price target on Cellebrite to $20 from $22 and keeps an Overweight rating on the shares as part of a security software earnings preview. Demand remained relatively healthy for high priority budget categories, with identity and data security increasing in priority, the analyst tells investors in a research note. The firm established 2026 based price targets across its coverage for those that have not yet been updated.
JPMorgan
Overweight
downgrade
$29 -> $25
2025-05-12
Reason
JPMorgan
Price Target
$29 -> $25
2025-05-12
downgrade
Overweight
Reason
JPMorgan lowered the firm's price target on Cellebrite to $25 from $29 and keeps an Overweight rating on the shares. The firm cites recent peer multiple contraction for the target cut. Cellebrite has the greatest level of government and federal exposure within the sector, which continues to pressure the stock, the analyst tells investors in a research note. However, JPMorgan remains optimistic on the shares, saying industry conversations reflect strong demand from spending initiatives Cellebrite has exposure to, implying concerns are likely overdone.
Needham
Mike Cikos
Strong Buy
Reiterates
$28
2025-04-02
Reason
Needham
Mike Cikos
Price Target
$28
2025-04-02
Reiterates
Strong Buy
Reason
Needham
Mike Cikos
Strong Buy
Reiterates
$28
2025-03-27
Reason
Needham
Mike Cikos
Price Target
$28
2025-03-27
Reiterates
Strong Buy
Reason
Needham
Mike Cikos
Strong Buy
Reiterates
$28
2025-03-10
Reason
Needham
Mike Cikos
Price Target
$28
2025-03-10
Reiterates
Strong Buy
Reason
Needham
Mike Cikos
Strong Buy
Reiterates
$28
2025-02-14
Reason
Needham
Mike Cikos
Price Target
$28
2025-02-14
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Cellebrite DI Ltd (CLBT.O) is 30.94, compared to its 5-year average forward P/E of 46.97. For a more detailed relative valuation and DCF analysis to assess Cellebrite DI Ltd 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
46.97
Current PE
30.94
Overvalued PE
71.84
Undervalued PE
22.09

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average EV/EBITDA
26.10
Current EV/EBITDA
24.31
Overvalued EV/EBITDA
39.65
Undervalued EV/EBITDA
12.55

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
5.02
Current PS
7.11
Overvalued PS
7.54
Undervalued PS
2.49

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

CLBT News & Events

Events Timeline

(ET)
2025-07-08
08:51:00
Cellebrite names David Barter as CFO
select
2025-06-05 (ET)
2025-06-05
07:32:27
Cellebrite to acquire Corellium for enterprise value of $170M in cash
select
2025-05-14 (ET)
2025-05-14
07:10:50
Cellebrite sees FY25 revenue $470M-$485M, consensus $484.21M
select
Sign Up For More Events
Sign Up For More Events

News

Preview
4.0
07-10TipRanks
3 Best Stocks to Buy Now, 7/10/2025, According to Top Analysts
  • Top Stock Picks: Analysts recommend three stocks as Strong Buys: Cellebrite DI (CLBT) with a 44% upside, Energy Transfer (ET) with a 29% upside, and Fair Isaac (FICO) with a 38.96% upside, all receiving recent Buy ratings from top analysts.

  • Analyst Rankings: TipRanks provides real-time rankings of financial analysts based on their success rates and profitability, highlighting the accuracy of top-ranking analysts in stock recommendations.

Preview
5.0
07-08NASDAQ.COM
Cellebrite Appoints David Barter To Succeed Dana Gerner As CFO
  • Cellebrite Appoints New CFO: Cellebrite DI Ltd. has appointed David Barter as Chief Financial Officer, succeeding Dana Gerner, who will remain in an advisory role during the transition period.

  • Barter's Experience: David Barter brings over 30 years of financial leadership experience, having previously served as CFO at several technology companies, including New Relic and C3.ai.

Preview
7.5
06-25Newsfilter
Accelerating Child Exploitation Investigations: Cellebrite Integrates Data from the National Center for Missing and Exploited Children (NCMEC)
  • Cellebrite and NCMEC Partnership: Cellebrite has expanded its collaboration with the National Center for Missing and Exploited Children (NCMEC) to enhance investigations of child exploitation by integrating NCMEC's CyberTipline hash value list into its digital forensics software, enabling faster identification of known child sexual abuse material (CSAM).

  • Impact on Investigations: This integration is expected to significantly reduce the time needed to locate CSAM on devices, aiding law enforcement in arresting offenders more efficiently while also protecting investigators' mental health, thereby contributing to the ongoing efforts to combat online child exploitation.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Cellebrite DI Ltd (CLBT) stock price today?

The current price of CLBT is 14.59 USD — it has decreased -1.08 % in the last trading day.

arrow icon

What is Cellebrite DI Ltd (CLBT)'s business?

Cellebrite DI Ltd is an Israel-based company engaged primarily in the software sector. The Company is committed to providing a Digital Intelligence (DI) platform for managing DI in legally sanctioned investigations. The Company provides solutions for the public and private sectors, enabling organizations in mastering the complexities of legally sanctioned digital investigations by streamlining intelligence processes. The Company's platform and solutions transform how customers collect, review, analyze and manage data in legally sanctioned investigations. The Company aims to enable its customers to protect and save lives, accelerate justice, and preserve privacy in communities around the world.

arrow icon

What is the price predicton of CLBT Stock?

Wall Street analysts forecast CLBT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLBT is 23.25 USD with a low forecast of 20.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Cellebrite DI Ltd (CLBT)'s revenue for the last quarter?

Cellebrite DI Ltd revenue for the last quarter amounts to 107.55M USD, increased 20.06 % YoY.

arrow icon

What is Cellebrite DI Ltd (CLBT)'s earnings per share (EPS) for the last quarter?

Cellebrite DI Ltd. EPS for the last quarter amounts to 0.07 USD, decreased -119.44 % YoY.

arrow icon

What changes have occurred in the market's expectations for Cellebrite DI Ltd (CLBT)'s fundamentals?

The market is revising No Change the revenue expectations for Cellebrite DI Ltd. (CLBT) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -23.41%.
arrow icon

How many employees does Cellebrite DI Ltd (CLBT). have?

Cellebrite DI Ltd (CLBT) has 1167 emplpoyees as of July 13 2025.

arrow icon

What is Cellebrite DI Ltd (CLBT) market cap?

Today CLBT has the market capitalization of 3.49B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free